Sentences with phrase «with such tumors»

Not exact matches

And so early efforts centered on making sure the gas tank was filled — priming the immune system with cytokines (such as the interleukins) or with immune - signaling proteins like interferon to rev up the tumor - fighting response.

Teixeira and his team also found that a malfunctioning tumor - suppressing gene that's associated with certain cancers, such as colon and pancreatic, and is known as Stk11, additionally influenced the development of BPH.

«The minimum sample volume required is only 1 µL for analysis of 92 proteins, which has been proven to be a great advantage for applications with limited sample volumes, such as pediatric applications, fine - needle biopsies, and tumor microbiopsies,» he says.

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

So far, researchers with the Allen Institute for Brain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilepsy.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

The IBM Watson Health unit is perhaps the most prominent, with the company for the past several years claiming that its AI is assisting major medical centers and hospitals in tasks such as genetically sequencing brain tumors and matching cancer patients to clinical trials.

«If we could load these virus shells with a different cargo, say a drug, and target it to a particular place in the body, such as a tumor, it could then deliver the drug to just that specific location, making the drug more effective, or reducing side effects,» Lawrence said.

The second gene, TNFRSF6B, encodes a receptor related to those that bind tumor necrosis factor (TNF)-- a key chemical signal for triggering inflammation in IBD as well as in patients with other autoimmune disorders such as rheumatoid arthritis and psoriasis.

Most cancer vaccines developed to date have been designed to recognize and attack a specific known molecule — such as a cell - surface receptor — that is likely to be found on cancerous cells in any patient with that type of tumor.

«Can this technique provide both EGFR mutation status information at the molecular level and precise anatomical information such as size, shape, NSCLC tumor location (s), and their relationship with adjacent structures?.»

The approach is already routine for some cancer patients, such as women and men with breast cancer tumors that have high levels of a protein called HER2, or lung cancer tumors with mutations in the EGFR gene.

Within a single tumor exists such an astonishingly varied population of cells, each with its own combination of normal and abnormal genes, that at least some cells nearly always have a way to survive any particular attack.

«Though many challenges still remain, such work could potentially transform treatment outcomes for patients with glioblastoma and related brain tumors, for which current therapies provide limited benefits.»

These drugs are also frequently used to manage central nervous system (CNS) disorders associated with a pathologically permeable BBB, such as with brain tumors and multiple sclerosis.

If enacted, such a regulatory scheme could conceivably speed along clinical trials because it would allow investigators to draw from a large pool of people with diverse tumors that act along the same pathway instead of culling thousands of people with the same official cancer type.

Unaltered cells created tumors in all seven mice injected with such cells, but when cells missing ALKBH5 were used, they caused tumors in only 43 percent (six out of 14) of mice.

«We also found that the tumors developed quickly, at the time in early development that corresponds to when such tumors develop in children with the cancer.»

Advances such as a new understanding of cancer as a genomic disease and successes with immunotherapy — harnessing the immune system to thwart tumors — mean that «the time is right for a renewed surge against cancer,» they write.

In collaboration with the University of Texas Southwestern Medical Center (UTSW) in Dallas, the researchers found that the tumor - suppressive activity of geranylgeraniol was accompanied by down - regulation of HMG CoA reductase, a key enzyme in the mevalonate pathway that provides essential intermediates for the posttranslational modification of growth - related proteins such as Ras, nuclear lamins and insulin - like growth factor receptors.

«The treatment of multiple myeloma has improved significantly in recent years with the introduction of therapies such as proteasome inhibitors [which interfere with tumor cells» protein - disposal system] and potent immuno - modulatory agents,» said the paper's senior author and lead investigator, Paul Richardson, MD, clinical program leader and director of clinical research at Dana - Farber's Jerome Lipper Multiple Myeloma Center, and the R.J. Corman professor at Harvard Medical School.

The disease itself, with its multiple tumors, suggests the handiwork of such a gene gone awry.

Both Tsigelny and Kurzrock agreed that this finding is an excellent example of the power of collaboration between SDSC and the Moores Cancer Center, and that such modeling needed to be studied across tumors and with multiple different genes involved in cancer.

The authors conclude that FL118 - based therapy may be beneficial for a subgroup of cancer patients with tumors such as chronic lymphocytic leukemia and melanomas, in which MdmX overexpression confers treatment resistance.

Surprisingly, they found that although the patterns of gene expression — as shown by the RNA sequencing — differed between the hepatocellular carcinomas and the liver cancers with biliary phenotype and depended on the histological type, the overall pattern of mutations in the cells was actually similar between the tumors — of either type — that had emerged in patients who had had infections with either hepatitis C or B, and were different in patients without such infections.

Reactivation of HBV may occur with chemotherapy, organ and tissue transplantation, High dose corticosteroids, and biologicals targeting tumor necrosis factor - alpha (TNF - α), Anti-TNF medications are used in treating rheumatic diseases, such as rheumatoid arthritis, digestive conditions that include Crohn's and colitis, and dermatologic conditions, such as psoriasis.

But in diseases such as breast cancer, the breakdown of this order has been associated with the rapid growth and spread of tumors.

In skin tumors the process can start with a change in a single gene, such as H - ras.

Block or remove the estrogen with different types of drugs, such as the commonly prescribed tamoxifen or aromatase inhibitors, and the tumor stops growing.

Answering important clinical questions — such as whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.

The scientists also found consistent evidence of increased pro-inflammatory markers, such as C - reactive protein and tumor necrosis factor alpha, associated with PTSD.

The study further suggests that NSAIDs such as aspirin, ibuprofen and naproxen have a particularly advantageous effect when taken after diagnosis by colorectal, or CRC, patients without tumor mutation in the KRAS gene (KRAS wild - type tumors): The study shows that NSAID use by this group is associated with a survival benefit of 40 percent.

But the «defective» repair capability is a process that may be exploited by treatments, such as PARP inhibition, which further impairs the ability of tumors to repair their own DNA after insult with radiation.

Researchers leading the largest genomic tumor profiling effort of its kind say such studies are technically feasible in a broad population of adult and pediatric patients with many different types of cancer, and that some patients can benefit by receiving precision drugs targeted to their tumors» mutations or being enrolled in clinical trials.

Such a positive survival rate is encouraging considering that historically conventional RT resulted in poor tumor control for patients with inoperable lung cancer.

That would be a huge boon for therapy by allowing doctors to combine visual imaging, such as MRI scans, of tumors with knowledge of their genetic make - up, says experimental oncologist Janusz Rak of McGill University Health Centre in Montreal, Canada.

Friedman notes that, even with the increasing number of drugs targeting specific molecular abnormalities that drive tumor growth, most patients are only treated with one such drug at a time.

Teixeira and his team also found that a malfunctioning tumor - suppressing gene that's associated with certain cancers, such as colon and pancreatic, known as Stk11, additionally influenced the development of BPH.

Finding cancer early can improve a patient's chances for survival, but small tumors can be difficult to see with scanning techniques such as magnetic resonance...

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

For more information regarding Bristol - Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: • Early stage IB - IIIA, operable non-small cell lung cancer, confirmed in tissue • Lung function capacity capable of tolerating the proposed lung surgery • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 - 1 • Available tissue of primary lung tumor Exclusion Criteria: • Presence of locally advanced, inoperable or metastatic disease • Participants with active, known or suspected autoimmune disease • Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors) Other protocol defined inclusion / exclusion criteria could apply

We need a new type of vaccine that uses select components of a microbe or tumor cell or other cause of disease, and administers these with other defined substances, such as adjuvants, that directly exploit immunology.»

A Ludwig Cancer Research study has uncovered a key mechanism by which tumors develop resistance to radiation therapy and shown how such resistance might be overcome with drugs that are currently under development.

In our laboratory we had the idea of localizing on tumor cells, with specific monoclonal antibodies, molecules, such as Major Histocompatibility Complexe (MHC), loaded with viral peptides, which can activate the T lymphocytes to attack the target tumor cells.

Tumor - infiltrating CD8 + T cells with high CD39 expression exhibited features of exhaustion, such as reduced production of TNF and IL - 2 and expression of co-inhibitory receptors.

Yongwon Choi, with Ralph Steinman and others, identifies a new tumor necrosis factor family member TRANCE (later called RANKL), [i] and subsequently demonstrates its role in the immune and bone system, and also in bone - residing cancers such as multiple myelomas.

These so - called «living drugs» — injected T cells genetically modified to better recognize and kill tumor cells through a perpetual process of cell renewal and expansion — are revolutionizing cancer treatment, with the first two FDA approvals of such gene - altering therapies occurring in just the last two months.

Therefore the dosage of administration has to change at it has been previously observed with other treatment modalities such as; inhaled insulin.35, 37 A major obstacle regarding the distribution of aerosol within the airways is atelectasis, tumor mass or pleural effusion.

The Bone Marrow and Stem Cell Transplant Program is expanding the use of this technique for patients with solid tumors including neuroblastoma and brain tumors; a variety of high - risk hematologic diseases, such as thalassemia major and transfusion - dependent sickle cell disease; and other nonmalignant diseases.

Nevertheless, the field is — also due to the lack of standard conditions for important methods — currently struggling with many issues such as the challenge of developing a clear definition of what tumor stem cells actually are and how they can be identified.